StockTipsArenaBeta

SELL Biocon Ltd — ICICI Securities

SELLBiocon Ltd
Biocon share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)9 Aug 2025via Institutional / Brokerage Research

Entry₹343.35Inferred
Target₹270
Total upside +21.36% (call closed)
Stop lossNot given
At expiry₹426.357 Aug 2026, 3:30 pm
Expired-24.17%auction close
Follow ICICI Securities for new calls(67% target hit, 1027 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 10 active Long-term calls on BIOCONSee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Aug 2026
1 supporting7 neutral21 opposing
Supports the SELL call (1)

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·15 Jul · 3w ago

Neutral / worth noting (7)

From profit surges to margin worries: The big takeaways from Wednesday's earnings

NewsCnbc-Tv18·5 Aug · yesterday

(opens in new tab)

Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · yesterday

(opens in new tab)

Q1 Results Today Highlights: Godrej Agrovet posts mixed Q1; Whirlpool PAT falls 34%, Berger Paints, Biocon, Shilpa Medicare, Aster DM, Navin Fluorine report profit growth

NewsHbl·5 Aug · 2d ago

(opens in new tab)

Market Pulse: Key triggers to watch before the Aug 5 trading session

NewsCnbc-Tv18·4 Aug · 2d ago

(opens in new tab)
Weighs against the SELL call (21)

Biocon Shares Surge Nearly 3% After Q1 Profit Jumps 350%

NewsNdtv-Profit·6 Aug · yesterday

(opens in new tab)

Biocon Q1 Results: Profit Spikes 350%, Revenue Exceeds Rs 4,300 Crore

NewsNdtv-Profit·5 Aug · yesterday

(opens in new tab)

Biocon Q1 Results: Net profit jumps over four-fold as biopharma business drives growth

NewsCnbc-Tv18·5 Aug · yesterday

(opens in new tab)

Biocon Q1FY27 Total Income at Rs 4,391 Cr (up 9%), EBITDA at Rs 902 Cr, Net Profit at Rs 141 Cr, with Biopharma Revenue up 17%.

NSE · Press Release·5 Aug · yesterday

(opens in new tab)

3 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·6 Aug · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from ICICI Securities

Every call and its outcome